地屈孕酮延长周期与连续方案均可有效缓解子宫内膜异位症慢性盆腔痛:ORCHIDEA研究
两方案均显著降低疼痛评分(分别较基线变化-3.3±2.2和-3.0±2.2),组间无显著差异,安全性良好,未报告严重药物不良反应。
要点
- 地屈孕酮延长周期与连续方案均显著降低慢性盆腔痛评分,组间无显著差异。
- 两方案均改善镇痛药使用天数、痛经严重程度、性健康及健康相关生活质量。
- 研究期间未报告严重药物不良反应,安全性良好。
核心结论
- 地屈孕酮延长周期方案与连续方案均对子宫内膜异位症相关慢性盆腔痛和痛经产生显著且相似的减轻作用,并全面改善生活质量与性健康相关指标。
研究设计与样本
- 干预为地屈孕酮10 mg每日2或3次,采用月经周期第5–25天的延长周期方案或连续方案,所有患者数据截止于治疗6个月。
主要发现
- 延长周期方案与连续方案均显著降低慢性盆腔痛强度,平均±标准差较基线变化分别为-3.3±2.2和-3.0±2.2,组间无显著差异。
- 两方案均显著改善慢性盆腔痛强度、需使用镇痛药的天数、痛经严重程度、性健康及健康相关生活质量参数。
- 地屈孕酮安全性良好,研究期间未报告严重药物不良反应。
关键数值与推荐
- 主要结局为治疗6个月时11点数字评定量表评估的慢性盆腔痛强度。
- 延长周期方案:地屈孕酮10 mg每日2或3次,于月经周期第5–25天给药。
- 连续方案:地屈孕酮10 mg每日2或3次连续给药。
临床怎么用
- 对于子宫内膜异位症相关慢性盆腔痛,地屈孕酮延长周期或连续方案均可作为可选治疗,两者镇痛效果相似。
- 治疗6个月可预期疼痛、痛经、镇痛药需求及生活质量的多维度改善,且安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of two different treatment regimens of dydrogesterone in the management of endometriosis-related chronic pelvic pain. DESIGN: Observational, prospective cohort study over six months. SETTING: Twenty gynecology clinics in the Russian Federation. PATIENT(S): Three hundred fifty women from 18 to 45 years of age with endometriosis and chronic pelvic pain with or without dysmenorrhea. INTERVENTION(S): Dydrogesterone 10 mg 2 or 3 times daily, either between the 5th and 25th days of the menstrual cycle (prolonged cyclical treatment regimen) or continuously (continuous treatment regimen). For all patients, the data cutoff was at six months of treatment. MAIN OUTCOME MEASURE(S): Intensity of chronic pelvic pain on the 11-point numerical rating scale (after 6 months). RESULT(S): A marked reduction in chronic pelvic pain was observed with both the prolonged cyclical and continuous treatment regimens (mean ± standard deviation change from baseline -3.3 ± 2.2 and -3.0 ± 2.2, respectively), with no significant difference between the two groups. With both regimens, patients experienced significant improvements in the intensity of chronic pelvic pain, number of days in which analgesics were required, severity of dysmenorrhea, sexual well-being, and health-related quality-of-life parameters. A favorable safety profile of dydrogesterone was confirmed, and no serious adverse drug reactions were reported during the study. CONCLUSION(S): Prolonged cyclical and continuous treatment regimens of dydrogesterone therapy both demonstrated a pronounced and similar reduction in the severity of chronic pelvic pain and dysmenorrhea and led to marked improvements in all study parameters related to quality of life and sexual well-being. REGISTRATION NUMBER: NCT03690765.
引用
- Sukhikh GT, Adamyan LV, Dubrovina SO, et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil Steril. 2021. PMID: 34465452. doi:10.1016/j.fertnstert.2021.07.1194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。